explore -WSS

explore

author：comprehensive 2025-09-03 14:35:36 - browse：474

Chris O'Meara/AP

Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers.

Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations. Those overpayments, the lawsuit alleges, ultimately come out of workers’ paychecks in the form of high health insurance premiums, higher out-of-pocket drug costs, and stunted wage growth.

In one example, J&J allegedly paid its PBM more than $10,000 for a single 90-day prescription of teriflunomide, a generic medicine for multiple sclerosis, when that same 90-day prescription could be purchased for as little as $30 elsewhere without insurance, according to the lawsuit.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： AstraZeneca stays mum on Medicare drug pricing negotiations

focus

WSS

Updated Covid vaccine has 54% effectiveness, new study suggests

FTC falls short on scrutinizing hospital mergers, study says

After traumatic brain injury, life support decisions can use more time

Q&A: Jennifer Adair on making gene therapy available globally

Why does health care cost so much? A reading guide

AstraZeneca stays mum on Medicare drug pricing negotiations

entertainment

explore

hotspot

Tori Bowie and the unacceptable rates of Black maternal death

Cell therapy fails to slow type 1 diabetes, but safety is established

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Medical bills so high, Medicare adding extra digits to claim forms

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

More tobacco lobbyists active in statehouses

Supreme Court strikes down use of affirmative action

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Bright Health sells Medicare Advantage business to Molina

Exact Sciences stock tumbles despite strong cancer detection sales

entertainment

The CDC's new social media misinformation war

Dogs on Prozac: What pet anti

H5N1 bird flu found in pasteurized milk: what we know

Close Medicare's dangerous gaps in addiction treatment coverage

A single Democrat is willing to weaken Medicare negotiation power

The CDC's new social media misinformation war

leisure time

focus

Wikipedia

hotspot